Get started
Author

Takayuki Kamikawa

Observed name: T. Kamikawa
ORCID: 0009-0008-6118-3871
Observed ORCID: 0009-0008-6118-3871
OpenAlex ID: A5020139752
Exploitation of Elevated Extracellular ATP to Specifically Direct Antibody to Tumor Microenvironment
2020 · Futa Mimoto, Kanako Tatsumi, et al. · Cell Reports · 75
PDF
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
2013 · Futa Mimoto, Tomoyuki Igawa, et al. · mAbs · 73
PDF
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137
2024 · Takayuki Kamikawa, Naoki Kimura, et al. · Journal for ImmunoTherapy of Cancer · 29
PDF
Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs
2013 · F. Mimoto, S. Kadono, et al. · Molecular Immunology · 26
PDF
Serological Evidence of Leptospiral Infection in Pig Populations in Different Districts in Japan
2007 · Michiko Naito, Yoshihiro Sakoda, et al. · Microbiology and Immunology · 21
PDF
Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD)
2016 · Terushige Muraoka, Mitsuaki Ide, et al. · Bioorganic & Medicinal Chemistry · 15
Identification of a selective inhibitor of transforming growth factor β-activated kinase 1 by biosensor-based screening of focused libraries
2016 · Takaaki Miura, Atsushi Matsuo, et al. · Bioorganic & Medicinal Chemistry Letters · 4
CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al. · Cancer Research Communications · 2
1172 SAIL66, a next generation of T cell engager targeting CLDN6, potentiates efficacy
2023 · Takayuki Kamikawa, Naoki Kimura, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Supplementary Fig S6 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Supplementary Fig S4 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Supplementary Fig S1 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Supplementary Fig S5 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Supplementary Fig S2 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Supplementary Table S3 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Figure 7 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Figure 1 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Supplementary Table S2 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Figure 4 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Supplementary Fig S7 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Figure 6 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Supplementary Fig S10 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Figure 8 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Figure 3 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Supplementary Table S1 from CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy
2026 · Naoki Kimura, Kenji Taniguchi, et al.
Works count: 33
Citation count: 246
H-index: 6
I10-index: 6
Year
Topic
Type